CYP2C19, cytochrome P450 family 2 subfamily C member 19, 1557
N. diseases: 274; N. variants: 14
Source: ALL
| Disease | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year |
|---|---|---|---|---|---|---|---|
|
|
0.100 | Biomarker | disease | BEFREE | Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. | 10616772 | 1999 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Twenty-five white patients were genotyped for CYP2C19 by allele-specific polymerase chain reaction amplification, and their Helicobacter pylori status was assessed by serology and with immunoblot analysis. | 10982760 | 2000 |
|
|
0.100 | Biomarker | disease | BEFREE | Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations. | 12132671 | 2002 |
|
|
0.100 | GeneticVariation | disease | BEFREE | To investigate the effect of different proton pump inhibitors, S-mephenytoin 4'-hydroxylase (CYP2C19) genotype and antibiotic susceptibility on the eradication rate of Helicobacter pylori. | 12534411 | 2003 |
|
|
0.100 | Biomarker | disease | BEFREE | Helicobacter pylori treatment failure is thought to be due mainly to polymorphic cytochrome P450 2C19 (CPY2C19) genetic polymorphism, associated with proton pump inhibitor metabolism, and antimicrobial susceptibility. | 12544691 | 2003 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Methods : We determined CYP2C19 genotypes (CYP2C19*1, *2 and *3) in 111 Helicobacter pylori-positive patients with gastric cancer and 315 H. pylori-positive controls without gastric cancer consisting of patients with gastritis only or peptic ulcer. | 16268979 | 2005 |
|
|
0.100 | Biomarker | disease | BEFREE | We intended to determine SNPs of CYP2C19 and 23S rRNA of Helicobacter pylori by using rapid urease test (RUT)-positive gastric mucosal samples. | 15952098 | 2005 |
|
|
0.100 | Biomarker | disease | BEFREE | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. | 15691303 | 2005 |
|
|
0.100 | GeneticVariation | disease | BEFREE | It has been suggested that proton pump inhibitor (PPI)-related differences in Helicobacter pylori eradication rates are partly because of CYP2C19 polymorphisms and there have been conflicting data in this area. | 16863547 | 2006 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. | 16912869 | 2006 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Fifteen Helicobacter pylori-positive volunteers with 3 different CYP2C19 genotypes were administered twice-daily intravenous infusions of 20 mg famotidine alone, 20 mg omeprazole alone, 10 mg omeprazole plus 10 mg famotidine (half-concomitant regimen), and 20 mg omeprazole plus 20 mg famotidine (full-concomitant regimen) for 2 days. | 17112810 | 2006 |
|
|
0.100 | Biomarker | disease | BEFREE | Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. | 16843075 | 2006 |
|
|
0.100 | GeneticVariation | disease | BEFREE | To investigate whether MDR1 polymorphism is associated with eradication rates of Helicobacter pylori by a triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP2C19 genotype status and bacterial susceptibility to clarithromycin. | 17697203 | 2007 |
|
|
0.100 | GeneticVariation | disease | BEFREE | The potential contribution of CYP2C19 genetic polymorphisms and the presence of Helicobacter pylori were also assessed. | 17645482 | 2007 |
|
|
0.100 | Biomarker | disease | BEFREE | Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect? | 17410461 | 2007 |
|
|
0.100 | GeneticVariation | disease | BEFREE | We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. | 18637061 | 2008 |
|
|
0.100 | Biomarker | disease | BEFREE | MeSH terms and keywords included proton pump inhibitor, omeprazole, lansoprazole, rabeprazole, pantoprazole, or esomeprazole, cytochrome P4502C19 or CYP2C19, and Helicobacter pylori or H. pylori. | 19166419 | 2008 |
|
|
0.100 | Biomarker | disease | BEFREE | AUC of rabeprazole in 18 Helicobacter pylori-negative GERD subjects (five CYP2C19 homozygous extensive metabolizers [homEM], eight heterozygous extensive metabolizers [hetEM] and five poor metabolizers [PM]) were determined after the final medication. | 17725594 | 2008 |
|
|
0.100 | GeneticVariation | disease | BEFREE | But no study correlated CYP2C19 genetic polymorphism with eradication of Helicobacter pylori in north Indian gastritis patients positive for H. pylori and hence this study. | 19942749 | 2009 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori. | 19552744 | 2009 |
|
|
0.100 | GeneticVariation | disease | BEFREE | CYP2C19*2, *3, *4, *5 and *17 genotypes were determined in healthy Helicobacter pylori-negative Caucasian subjects. | 19785625 | 2010 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Correlation of CYP2C19 genetic polymorphisms with helicobacter pylori eradication in patients with cirrhosis and peptic ulcer. | 20457439 | 2010 |
|
|
0.100 | GeneticVariation | disease | BEFREE | We determined the incidence of cytochrome P450 2C19 genotypes and the effect of cytochrome P450 2C19 genotypes on Helicobacter pylori eradication rates in 105 patients with Helicobacter pylori-positive chronic gastritis. | 20533108 | 2010 |
|
|
0.100 | GeneticVariation | disease | BEFREE | Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication. | 21361732 | 2011 |
|
|
0.100 | GeneticVariation | disease | BEFREE | In this study, we examined the usefulness of the prediction of the pharmacotherapeutic efficacy using a newly developed analysis system for HP CAM resistance and CYP2C19 genotypes. | 21132257 | 2011 |